SCHEMBL1860201

SCHEMBL1860201

Cc1cc(C(C[C@H]2CCC(=O)C2)C(=O)Nc2ccn(CC(C)(C)O)n2)ccc1S(C)(=O)=O

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCK P35557 17/20 0.55
KCNH2 Q12809 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1860200 1.00 GCK (0.55) GCKKCNH2
SCHEMBL1859425 0.92 GCK (0.67) GCKKCNH2
SCHEMBL5139742 0.92 GCK (0.67) GCKKCNH2
SCHEMBL1859431 0.92 GCK (0.67) GCKKCNH2
SCHEMBL1863818 0.91 GCK (0.56) GCKKCNH2
SCHEMBL1863810 0.91 GCK (0.56) GCKKCNH2
SCHEMBL1863970 0.90 GCK (0.54) GCKKCNH2
SCHEMBL1863976 0.90 GCK (0.54) GCKKCNH2
SCHEMBL1857216 0.90 KCNH2 (0.52) GCKKCNH2
SCHEMBL1861136 0.90 KCNH2 (0.50) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 GCK 2/4885KCNH2 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.